The Food and Drug Administration (FDA) has approved the first respiratory syncytial virus (RSV) vaccine for use in the U.S., the public health agency announced on Wednesday.
The Food and Drug Administration has approved the first respiratory syncytial virus vaccine for use in the U.S.
In older adults, RSV infections can lead to lung infection or pneumonia, and also could cause complications in those who have asthma,The drug, called Arexvy , is approved for use by people 60 years and older to prevent RSV, which is a lower respiratory tract disease. "To put that in perspective, there were seven RSV cases in the vaccine group and 40 cases in the placebo group," Dr. Shana Johnson, a physical medicine and rehabilitation physician, told Fox News Digital."Reducing severe disease, such as hospitalizations and death, are the critical benefits."
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
FDA approves world's first RSV vaccine, a shot for adults ages 60 and upBREAKING: FDA approves the world's first respiratory syncytial virus, or RSV, vaccine made by pharmaceutical giant GSK.
Baca lebih lajut »
FDA approves first vaccine for RSV, a moment six decades in the making | CNNAfter a 60-year scientific quest, the world has its first vaccine to protect against respiratory syncytial virus, or RSV -- and more are on the way.
Baca lebih lajut »
FDA approves first RSV vaccine to protect older adultsUp to 10,000 deaths and 160,000 hospitalizations a year are caused by RSV.
Baca lebih lajut »
The First Vaccine for RSV Just Got FDA ApprovalIn a large Phase III trial, GlaxoSmithKline's Arexvy substantially reduced people's risk of severe complications from respiratory syncytial virus infection.
Baca lebih lajut »
FDA approves world’s first RSV vaccine, a shot for older adultsIn a late-stage clinical trial, the single-dose shot lowered the risk of symptomatic illness by 83% and of severe illness by 94%.
Baca lebih lajut »